Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
Journal of Pathology and Translational Medicine. 2021;55(3):163-170 
Programmed death ligand‐1/programmed death‐1 inhibition therapy and programmed death ligand‐1 expression in urothelial bladder carcinoma
Chronic Diseases and Translational Medicine. 2019;5(3):170-177
Editorial Comment to Programmed cell death‐ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma
International Journal of Urology. 2021;29(1):91-91
Inter‐ and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma
Histopathology. 2019;76(2):191-200
Lower neutrophil‐to‐lymphocyte ratio and positive programmed cell death ligand‐1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma
Cancer Medicine. 2022;
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
Diagnostic Pathology. 2019;14(1):
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations
Journal for ImmunoTherapy of Cancer. 2015;3(1):
Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
Frontiers in Oncology. 2021;10:
Programmed cell death‐ligand 1 expression in different molecular subtypes of upper tract urothelial carcinoma
International Journal of Urology. 2021;29(1):89-90
Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials
Frontiers in Oncology. 2021;11: